MedTrace Logo

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

NCT02334553 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-02-18

No results posted yet for this study

Summary

Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.

Conditions

Interventions

DRUG

S1226(8%)

The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.

DRUG

Placebo

Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response

Sponsors & Collaborators

  • SolAeroMed Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Leigh, MD, PhD · Professor and Head, Respiratory Clinical Trials Centre

  • Veronica Swystun, PhD · Respiratory Clinical Trials Centre, University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-06
Primary Completion
2015-11-25
Completion
2015-11-25

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334553 on ClinicalTrials.gov